ATE458754T1 - Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper - Google Patents

Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Info

Publication number
ATE458754T1
ATE458754T1 AT06707413T AT06707413T ATE458754T1 AT E458754 T1 ATE458754 T1 AT E458754T1 AT 06707413 T AT06707413 T AT 06707413T AT 06707413 T AT06707413 T AT 06707413T AT E458754 T1 ATE458754 T1 AT E458754T1
Authority
AT
Austria
Prior art keywords
diffusable
antibodies
beta oligomers
globulomers
derivatives
Prior art date
Application number
AT06707413T
Other languages
English (en)
Inventor
Heinz Hillen
Andreas Striebinger
Patrick Keller
Stefan Barghorn
Ulrich Ebert
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE458754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Application granted granted Critical
Publication of ATE458754T1 publication Critical patent/ATE458754T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AT06707413T 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper ATE458754T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05004858 2005-03-05
US66447705P 2005-03-23 2005-03-23
EP05006568 2005-03-24
US74086605P 2005-11-30 2005-11-30
PCT/EP2006/001984 WO2006094724A2 (en) 2005-03-05 2006-03-03 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies

Publications (1)

Publication Number Publication Date
ATE458754T1 true ATE458754T1 (de) 2010-03-15

Family

ID=36581967

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06707413T ATE458754T1 (de) 2005-03-05 2006-03-03 Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a- beta-oligomere und verfahren zur herstellung dieser antikörper

Country Status (14)

Country Link
US (1) US20090035295A1 (de)
EP (2) EP1861422B1 (de)
KR (1) KR20080021585A (de)
CN (1) CN101365717A (de)
AT (1) ATE458754T1 (de)
AU (1) AU2006222193B2 (de)
BR (1) BRPI0608076A2 (de)
CA (1) CA2599792A1 (de)
DE (1) DE602006012459D1 (de)
ES (1) ES2340414T3 (de)
IL (1) IL185392A0 (de)
MX (1) MX2007010687A (de)
WO (1) WO2006094724A2 (de)
ZA (1) ZA200707234B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2082749A3 (de) 2000-07-07 2010-06-30 Bioarctic Neuroscience AB Vorbeugung und Behandlung für Morbus Alzheimer
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CN101277974A (zh) 2005-09-30 2008-10-01 阿伯特有限及两合公司 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途
BRPI0619249A2 (pt) * 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
AU2013200177B2 (en) * 2005-11-30 2014-10-02 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against amyloid beta protein and uses thereof
MX2008007477A (es) * 2005-12-12 2008-09-03 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
BRPI0709050B1 (pt) 2006-03-23 2018-12-26 Bioarctic Neuroscience Ab anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
AU2008204335B2 (en) 2007-01-11 2013-06-13 Michael Bacher Diagnosis and treatment of Alzheimer's and other neurodementing diseases
EP2124952A2 (de) * 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
DK2170389T3 (en) * 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
EP2650308A3 (de) * 2007-10-05 2014-11-12 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenerkrankungen
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
EP2210901A4 (de) * 2007-10-19 2012-04-25 Immunas Pharma Inc Zur spezifischen bindung an ein oligomer fähiger antikörper, und dessen verwendung
EP2246427B1 (de) 2008-02-08 2016-11-30 Immunas Pharma, Inc. Antikörper mit fähigkeit zur spezifischen bindung an amyloid-beta oligomere und deren verwendung
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2010010469A2 (en) * 2008-07-25 2010-01-28 Abbott Gmbh & Co. Kg Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
WO2010011947A2 (en) * 2008-07-25 2010-01-28 Abbott Laboratories AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
RU2595720C2 (ru) 2009-04-09 2016-08-27 Когнишн Терапьютикс, Инк. Ингибиторы снижения когнитивных способностей
WO2010119704A1 (en) 2009-04-17 2010-10-21 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2010129276A2 (en) 2009-04-27 2010-11-11 Case Western Reserve University PYRO-GLUTAMATE Aβ TARGETING AGENTS
US9192585B2 (en) 2009-07-31 2015-11-24 Cognition Therapeutics, Inc. Inhibitors of cognitive decline
DK2462161T3 (en) * 2009-08-06 2017-06-06 Immunas Pharma Inc Antibodies specifically binding to A-beta oligomers and their use
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
KR20120118002A (ko) 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
WO2012054333A2 (en) * 2010-10-20 2012-04-26 Merck Sharp & Dohme Corp. Methods for identifying inhibitors of abeta42 oligomers
RU2013140467A (ru) 2011-02-02 2015-03-10 Когнишн Терапьютикс, Инк. Выделенные соединения из масла куркумы и способы применения
US9061006B2 (en) 2011-03-08 2015-06-23 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (PKU)
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
EP3369746A1 (de) 2012-01-27 2018-09-05 AbbVie Deutschland GmbH & Co KG Zusammensetzung und verfahren zur diagnose und behandlung von krankheiten im zusammenhang mit neuritenabbau
CA2867338A1 (en) * 2012-03-13 2013-09-19 Janssen Alzheimer Immunotherapy Oligomeric a.beta. in the diagnosis, prognosis, and monitoring of alzheimer's disease
AU2015210852B2 (en) 2014-01-31 2019-01-24 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
HRP20210680T1 (hr) 2014-07-10 2021-06-11 Bioarctic Ab POBOLJŠANA PROTUTIJELA KOJA VEŽU Aβ PROTOFIBRIL
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
KR101856838B1 (ko) * 2016-02-17 2018-06-19 이희정 베타-아밀로이드 올리고머에 대한 압타머 및 이의 용도
CN106519029B (zh) * 2016-10-31 2020-03-17 山东泰邦生物制品有限公司 一种Aβ寡聚体抗体的制备工艺
DK3634394T3 (da) 2017-05-15 2026-03-02 Cognition Therapeutics Inc Sammensætninger til behandling af neurogenerative sygdomme
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
CN109851668B (zh) * 2018-12-26 2022-12-23 广东菲鹏生物有限公司 一种saa蛋白免疫原及其制备方法和抗人血清淀粉样蛋白a多克隆抗体
CN111085011B (zh) * 2019-12-30 2021-12-03 中南民族大学 一种分子印迹磁性纳米材料的制备方法及其在γ-氨基丁酸提纯中的应用
CN117024554A (zh) * 2023-05-30 2023-11-10 中国人民解放军空军军医大学 一种Aβ1-42寡聚体存储液的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705330A (en) 1995-04-14 1998-01-06 Abbott Laboratories Chemiluminescent immunoassay for antibody detection
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE19916417A1 (de) 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
US20020002270A1 (en) * 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
EP1571158B1 (de) * 1999-08-04 2009-10-14 University Of Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005037209A2 (en) 2003-10-14 2005-04-28 University Of South Florida A method for the separation anti-amyloid beta antibody with amyloid beta peptide

Also Published As

Publication number Publication date
DE602006012459D1 (de) 2010-04-08
MX2007010687A (es) 2008-01-28
AU2006222193A1 (en) 2006-09-14
KR20080021585A (ko) 2008-03-07
CA2599792A1 (en) 2006-09-14
AU2006222193B2 (en) 2011-11-17
IL185392A0 (en) 2008-02-09
CN101365717A (zh) 2009-02-11
US20090035295A1 (en) 2009-02-05
ZA200707234B (en) 2011-02-23
EP2204381A1 (de) 2010-07-07
ES2340414T3 (es) 2010-06-02
EP1861422A2 (de) 2007-12-05
EP1861422B1 (de) 2010-02-24
BRPI0608076A2 (pt) 2009-11-10
WO2006094724A2 (en) 2006-09-14
WO2006094724A3 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
DE602006012459D1 (de) Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper
ATE478084T1 (de) Verfahren zur herstellung von 4'- azidocytidinderivaten
ATE306252T1 (de) Verfahren zur herstellung kristalliner partikel zur inhalation
DE60335552D1 (de) Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
ATE463247T1 (de) Bupropion metaboliten zur behandlung von angstzuständen
DE602005002654D1 (de) Prozess zur Herstellung von Nano- und Mikrokapseln aus Spinnenseidenprotein
CY1107082T1 (el) Μεθοδος καθαρισμου αλβουμινης η οποια περιλαμβανει ενα σταδιο νανοδιηθησης, διαλυμα και συνθεση για θεραπευτικη χρηση που περιεχουν την ιδια
DE60033566D1 (de) Neue sertralinhydrochlorid polymorphe, verfahren zur herstellung und zur verwendung und diese enthaltende zusammensetzungen
EA200501615A1 (ru) (2-гидрокси-2-(4-гидрокси-3-гидроксиметилфенил)этиламино)пропилфенильные производные в качестве бета-2-агонистов
SG149045A1 (en) Novel fused pyrrolocarbazoles
MY149041A (en) Novel fused pyrrolocarbazoles
ATE464338T1 (de) Neuer schaumstoffmodifikator, aus diesem neuen schaumstoffmodifikator hergestellte schaumstoffe und verfahren zur herstellung dieser schaumstoffe
DE502004010130D1 (de) Proteinpulver und daraus erhaltenes proteinhaltiges getränk
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
ATE407127T1 (de) Verfahren zur herstellung von beraprost und dessen salzen
ATE401300T1 (de) Verfahren zur herstellung von valsartan und vorstufen davon
ATE354583T1 (de) Verfahren zur herstellung c-7 substituierter 5- androstene
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE442355T1 (de) Herstellung von 4,5-dialkyl-3-acylpyrrol-2- carbonsäurederivaten durch synthese nach fischer- fink und anschliebende acylierung
DE502004001985D1 (de) Verfahren zur Herstellung von expandiertem Graphit
ATE461934T1 (de) Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren
ATE337796T1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
ATE442361T1 (de) Verfahren zur herstellung kristalliner formen von orlistat
ATE356215T1 (de) Verfahren zur herstellung von 2,4-didesoxyhexosen und 2,4,6-tridesoxyhexosen
TW200700432A (en) Screening method, process for purifying of non-diffusible a β oligomers, selective antibodies against said non-diffusible a β oligomers and a process for manufacturing of said antibodies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties